Oncotarget

Corrections:

Correction: HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer

Anqi Li _, Zebing Liu, Ming Li, Shuling Zhou, Yan Xu, Yaoxing Xiao and Wentao Yang

PDF  |  How to cite

Oncotarget. 2017; 8:30619-30620. https://doi.org/10.18632/oncotarget.17542

Metrics: PDF 949 views  |   ?  

Present: There is a duplication of images within Figure 5F and a typing error within Figure 4B.

Correct: The proper figure images are shown below. The authors sincerely apologize for this error.

Original article: Oncotarget. 2016; 7:37966-78. DOI: 10.18632/oncotarget.9274.

Figure 4: LMK-235 inhibits BC cell proliferation and induces apoptosis. B. MDA-MB-231 and Hs-578T cells were treated with DMSO or 50 nM, 500 nM, or 1 μM LMK-235 for 24 hours. The levels of acetyl-histone H3 and total histone H3 were examined by western blot. GAPDH was used as a loading control.

Figure 5: LMK-235 synergizes with bortezomib in BC cells. F. MDA-MB-231 and Hs-578T cells were plated in Matrigel invasion chambers and treated with 200 nM LMK-235 and/or 5 nM bortezomib for 24 hours. Three separate experiments were conducted, and representative results are shown. Magnification, ×100. Columns indicate the average number of invading cells from 5 random microscopic fields. *p<0.05 compared with the DMSO group; **p<0.05 compared with the equivalent doses in the LMK-235- or bortezomib-treated groups.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17542